Denali Therapeutics Files 8-K for Regulation FD Disclosure
Ticker: DNLI · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1714899
| Field | Detail |
|---|---|
| Company | Denali Therapeutics Inc. (DNLI) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulation-fd, disclosure, corporate-action
TL;DR
**Denali just filed an 8-K for Regulation FD, expect news soon!**
AI Summary
Denali Therapeutics Inc. filed an 8-K on January 8, 2024, under Regulation FD Disclosure and Financial Statements and Exhibits. This filing indicates that Denali is making a public disclosure of material non-public information, likely related to an upcoming event or announcement, to ensure fair and equal access to information for all investors. For shareholders, this matters because it signals that significant news is on the horizon, which could impact the stock price depending on the nature of the disclosed information.
Why It Matters
This filing signals that Denali Therapeutics is about to disclose important information, which could significantly influence investor perception and stock valuation.
Risk Assessment
Risk Level: medium — The risk is medium because the content of the disclosure is not yet known, and it could be positive or negative for the stock.
Analyst Insight
A smart investor would monitor Denali Therapeutics Inc. closely for upcoming announcements following this Regulation FD disclosure, as the content could significantly impact the stock price.
Key Players & Entities
- Denali Therapeutics Inc. (company) — the registrant filing the 8-K
- January 8, 2024 (date) — date of earliest event reported and filing date
- Regulation FD Disclosure (other) — item information disclosed in the 8-K
- Financial Statements and Exhibits (other) — item information disclosed in the 8-K
Forward-Looking Statements
- Denali Therapeutics Inc. will make a significant announcement related to its operations or financial performance. (Denali Therapeutics Inc.) — high confidence, target: Q1 2024
FAQ
What is the purpose of Denali Therapeutics Inc.'s 8-K filing on January 8, 2024?
The 8-K filing by Denali Therapeutics Inc. on January 8, 2024, is for Regulation FD Disclosure and Financial Statements and Exhibits, indicating a public disclosure of material non-public information.
What is the earliest event reported date for this 8-K filing?
The earliest event reported date for this 8-K filing is January 8, 2024, as stated in the document.
Under which sections of the Securities Exchange Act of 1934 was this report filed?
This Current Report was filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is Denali Therapeutics Inc.'s business address?
Denali Therapeutics Inc.'s business address is 161 Oyster Point Blvd., South San Francisco, California 94080.
Is Denali Therapeutics Inc. an emerging growth company?
No, the filing indicates with an unchecked box that Denali Therapeutics Inc. is not an emerging growth company.
Filing Stats: 516 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2024-01-08 08:06:38
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 per share DNLI NASDAQ Global Select Mar
Filing Documents
- dnli-20240108.htm (8-K) — 32KB
- ex991pressrelease182024.htm (EX-99.1) — 53KB
- denali_txlogox02a.jpg (GRAPHIC) — 664KB
- 0001714899-24-000031.txt ( ) — 1125KB
- dnli-20240108.xsd (EX-101.SCH) — 2KB
- dnli-20240108_lab.xml (EX-101.LAB) — 23KB
- dnli-20240108_pre.xml (EX-101.PRE) — 12KB
- dnli-20240108_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 8, 2024, Denali Therapeutics Inc. (the "Company") issued a press release announcing an update on its programs and expected milestones for 2024 and the Company's participation in the 42 st Annual J.P. Morgan Healthcare Conference. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information furnished in this Item 7.01 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated January 8, 2024. 104 Cover Page Interactive Data File (formatted as Inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DENALI THERAPEUTICS INC. Date: January 8, 2024 By: /s/ Alexander O. Schuth Alexander O. Schuth, M.D. Chief Operating and Financial Officer